{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:39:18Z","timestamp":1768891158487,"version":"3.49.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jaip.2014.10.010","type":"journal-article","created":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T23:46:10Z","timestamp":1421365570000},"page":"162-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["The Use of Anti-IgE Therapy Beyond Allergic Asthma"],"prefix":"10.1016","volume":"3","author":[{"given":"Jeffrey R.","family":"Stokes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas B.","family":"Casale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2014.10.010_bib1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaip.2013.11.004","article-title":"Omalizumab for chronic urticaria","volume":"2","author":"Casale","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2014.10.010_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaip.2013.06.003","article-title":"Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use","volume":"1","author":"Khan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2014.10.010_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib4","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jaci.2010.12.1085","article-title":"Omalizumab is effective in nonautoimmune urticaria","volume":"127","author":"Ferrer","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1398-9995.2010.02472.x","article-title":"Omalizumab\u2014an effective and safe treatment of therapy-resistant chronic spontaneous urticaria","volume":"66","author":"Groffik","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2014.10.010_bib6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A\u00a0randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib7","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H(1) antihistamines: a randomized, placebo-controlled study","author":"Saini","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2014.10.010_bib8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2014.10.010_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.anai.2014.02.014","article-title":"Therapy of chronic urticaria: a simple, modern approach","volume":"112","author":"Kaplan","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamadermatol.2013.8705","article-title":"Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria","volume":"150","author":"Metz","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2014.10.010_bib12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"The EAACI\/GA(2) LEN\/EDF\/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2014.10.010_bib13","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib14","unstructured":"Xolair [package insert]. (revision); March\u00a02014."},{"key":"10.1016\/j.jaip.2014.10.010_bib15","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","author":"Chang","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2003.11.044","article-title":"Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils","volume":"113","author":"Lin","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000320233","article-title":"Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria","volume":"154","author":"Metz","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1710-1492-7-9","article-title":"Long-term benefits of omalizumab in a patient with severe non-allergic asthma","volume":"7","author":"Menzella","year":"2011","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1378\/chest.10-0128","article-title":"Beneficial effects of treatment with anti-IgE antibodies (omalizumab) in a patient with severe asthma and negative skin-prick test results","volume":"139","author":"van den Berge","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2014.10.010_bib21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/02770903.2012.757780","article-title":"Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry","volume":"50","author":"de Llano","year":"2013","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2014.10.010_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.12-1961","article-title":"A\u00a0proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma","volume":"144","author":"Garcia","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2014.10.010_bib23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/all.12149","article-title":"Usefulness of omalizumab in ten patients with severe occupational asthma","volume":"68","author":"Lavaud","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2014.10.010_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0091-6749(97)70202-1","article-title":"Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis","volume":"100","author":"Casale","year":"1997","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib25","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1001\/jama.286.23.2956","article-title":"Omalizumab Seasonal Allergic Rhinitis Trail Group. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial","volume":"286","author":"Casale","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2014.10.010_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mai.2000.108310","article-title":"Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis","volume":"106","author":"Adelroth","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2332\/allergolint.55.379","article-title":"Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis","volume":"55","author":"Okubo","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2014.10.010_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2332\/allergolint.R-08-164","article-title":"Anti-IgE antibody therapy for Japanese cedar pollinosis: omalizumab update","volume":"57","author":"Okubo","year":"2008","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2014.10.010_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2222.2007.02894.x","article-title":"Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis","volume":"38","author":"Nagakura","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2014.10.010_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000199719","article-title":"Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated","volume":"149","author":"Ogino","year":"2009","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1081-1206(10)62171-0","article-title":"Omalizumab, an anti-IgE antibody in the treatment of adults and adolescents with perennial allergic rhinitis","volume":"91","author":"Chervinsky","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jaip.2014.02.001","article-title":"Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials","volume":"2","author":"Tsabouri","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2014.10.010_bib33","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jaci.2009.02.016","article-title":"Anti-IgE therapy: clinical utility beyond asthma","volume":"123","author":"Casale","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib34","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaad.2013.05.035","article-title":"Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective","volume":"69","author":"Lacombe Barrios","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2014.10.010_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000350486","article-title":"Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial","volume":"162","author":"Iyengar","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/all.12234","article-title":"Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines","volume":"69","author":"Hotze","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2014.10.010_bib37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ppul.22937","article-title":"Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence","volume":"49","author":"Tanou","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2014.10.010_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/JAA.S34579","article-title":"Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab","volume":"5","author":"Collins","year":"2012","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2014.10.010_bib39","first-page":"CD010288","article-title":"Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","volume":"9","author":"Jat","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2014.10.010_bib40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib41","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2014.10.010_bib42","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2500\/ajr.2007.21.3060","article-title":"The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study","volume":"4","author":"Penn","year":"2007","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.jaip.2014.10.010_bib43","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMoa022613","article-title":"Effect of anti-IgE therapy in patients with peanut allergy","volume":"348","author":"Leung","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2014.10.010_bib44","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A\u00a0phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib45","doi-asserted-by":"crossref","first-page":"937.e2","DOI":"10.1016\/j.jaci.2013.12.1089","article-title":"Use of omalizumab to improve desensitization safety in allergen immunotherapy","volume":"133","author":"Larenas-Linnemann","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/pai.12098","article-title":"Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy","volume":"24","author":"Kopp","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaci.2005.09.036","article-title":"Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis","volume":"117","author":"Casale","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib48","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jaci.2011.04.009","article-title":"Rapid oral desensitization in combination with omalizumab therapy in patients with cow\u2019s milk allergy","volume":"127","author":"Nadeau","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/pai.12259","article-title":"Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg","author":"Lafuente","year":"2014","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib50","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","article-title":"A\u00a0pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients","volume":"132","author":"Schneider","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-10-7","article-title":"Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab","volume":"10","author":"B\u00e9gin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib52","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00431-011-1540-4","article-title":"Omalizumab in the treatment of eosinophilic esophagitis and food allergy","volume":"170","author":"Rocha","year":"2011","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jaip.2014.10.010_bib53","doi-asserted-by":"crossref","unstructured":"Fang JC, Hilden K, Gleich GJ, Emerson LL, Ogorman MA, Lowichik A, et\u00a0al. A pilot study of the treatment of eosinophilic esophagitis with omalizumab. Gastroenterology 2011;140:S-235.","DOI":"10.1016\/S0016-5085(11)60951-7"},{"key":"10.1016\/j.jaip.2014.10.010_bib54","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaip.2014.03.009","article-title":"Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report","volume":"2","author":"Sokol","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2014.10.010_bib55","doi-asserted-by":"crossref","first-page":"E78","DOI":"10.1002\/ppul.22884","article-title":"Successful management of Churg-Strauss syndrome using omalizumab as adjuvant immunomodulatory therapy: first documented pediatric case","volume":"49","author":"Iglesias","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2014.10.010_bib56","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2014.10.010_bib57","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.anl.2013.12.006","article-title":"Anti-IgE therapy to Kimura\u2019s disease: a pilot study","volume":"41","author":"Nonaka","year":"2014","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.jaip.2014.10.010_bib58","first-page":"448","article-title":"Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease","volume":"20","author":"Bobolea","year":"2010","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2014.10.010_bib59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5415\/apallergy.2014.4.2.126","article-title":"Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy","volume":"4","author":"Lee","year":"2014","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.jaip.2014.10.010_bib60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5114\/pdia.2014.40659","article-title":"Effectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust","volume":"31","author":"Kupry\u015b-Lipi\u0144ska","year":"2014","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jaip.2014.10.010_bib61","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5415\/apallergy.2014.4.2.129","article-title":"Omalizumab in recurring larynx angioedema: a case report","volume":"4","author":"Ozturk","year":"2014","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.jaip.2014.10.010_bib62","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1378\/chest.11-1881","article-title":"Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia","volume":"142","author":"Kaya","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2014.10.010_bib63","first-page":"305","article-title":"Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab","volume":"17","author":"de Klerk","year":"2013","journal-title":"J\u00a0AAPOS"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219814005078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219814005078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:08:01Z","timestamp":1761973681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219814005078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S2213219814005078"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2014.10.010","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of Anti-IgE Therapy Beyond Allergic Asthma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2014.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}